Zydus Company Profile
What is the competitive landscape for ZYDUS
ZYDUS has four hundred and eighteen approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-seven tentative approvals on ZYDUS drugs.
Summary for Zydus
| US Patents: | 1 |
| Tradenames: | 335 |
| Ingredients: | 325 |
| NDAs: | 418 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | CANDESARTAN CILEXETIL | candesartan cilexetil | TABLET;ORAL | 091390-004 | Aug 23, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Lifesciences | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216137-003 | Aug 7, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Lifesciences | DEXAMETHASONE | dexamethasone | TABLET;ORAL | 216282-003 | Feb 7, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms | GLYBURIDE AND METFORMIN HYDROCHLORIDE | glyburide; metformin hydrochloride | TABLET;ORAL | 206748-001 | Feb 29, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Zydus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| India | 651MU2014 | ⤷ Start Trial |
| South Africa | 201606075 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Start Trial |
| Philippines | 12016501686 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | C300357 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
| 0368388 | SPC/GB07/065 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 |
| 1675573 | 92427 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE |
| 2022495 | C202130051 | Spain | ⤷ Start Trial | PRODUCT NAME: ICOSAPENTO DE ETILO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1524; DATE OF AUTHORISATION: 20210326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1524; DATE OF FIRST AUTHORISATION IN EEA: 20210326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
